Free Submission Public Relations &
Deutsch English


SmallCapReview Initiates Coverage of Oncolytics Biotech and Telik Inc.

Print article Print article
2012-12-13 16:32:04 -, A leading site for news and information on small caps, penny stocks and microcaps is adding Oncolytics Biotech (Nasdaq: ONCY) and Telik Inc. (Nasdaq: TELK) to its list of stocks "On the Radar".

Oncolytics Biotech (ONCY) is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company’s lead product, REOLYSIN, a proprietary formulation of the human reovirus, is currently in late stage (Phase III) clinical testing in head and neck cancers. REOLYSIN has been utilized in nearly thirty clinical trials including translational, Phase I, Phase II (single arm and randomized), and Phase III studies in a broad range of cancer indications.

ONCY Investor Highlights

Announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers.

Announced three poster presentations covering expanded results from: a Phase II clinical

trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016).

Expanded enrollment in the first stage of our Phase III head and neck cancer clinical trial (REO 18) to include 167 patients, all of whom have now been enrolled, and introduced an additional patient segregation to differentiate between patients with local recurrent disease, with or without metastases, and patients with distal metastases while maintaining the blind.

Completed enrollment in a U.K. Phase I clinical trial using intravenously-administered REOLYSIN in combination with cyclophosphamide in patients with advanced malignancies.

Telik Inc. (TELK) is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic diseases including myelodysplastic syndrome and ICN; followed by Telcyta, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

TELK Investor Highlights

Announced today the publication of a clinical trial abstract in the proceedings of the 54th Annual Meeting of the America. Ezatiostat treatment of these ICN patients with grade 4 neutropenia who were not responsive to G‑CSF resulted in a durable increase in their white-blood-cell levels, leading to clinically significant reductions in serious infections.  Extended oral treatment with ezatiostat has been well tolerated in these patients and may be appropriate for longer-term therapy.

At September 30, 2012, Telik had $6.6 million in cash, cash equivalents and investments including restricted investments.

To learn more about ONCY and TELK visit

Features available at include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.

No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. has not been compensated by any of the above mentioned companies.

Copyright SmallCapReview. is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play.

Press Information:

2312 Healy Dr.
Winston-salem, NC 27017

Contact Person:
Thomas Englebert
Phone: 336-452-4669
email: email


Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact